EuroBiotech: More Articles of Note


> GammaDelta Therapeutics created a spinout company, Adaptate Biotherapeutics. The spinout will develop antibodies to modulate the activity of gamma delta T cells. Release 

> Amarna Therapeutics raised €10 million ($11 million) to move its SV40-based gene delivery vector platform toward human testing. The Dutch biotech expects to be in the clinic within three years. Statement 

> The city of Amsterdam put out a tender for the development of a medicines business park. The move is intended to build on the relocation of the European Medicines Agency to the city. Release

Sponsored by Clinical Ink

White Paper: Keep Your GI Trials Moving During COVID-19

Clinical Ink’s intimate knowledge of and experience with GI trials enables a better deployment experience and improved trial conduct. Learn how our GI-specific data capture solutions can support virtual and hybrid trials during COVID-19.

> Sotio obtained an option to license MaveriX Oncology’s solid tumor drug MVX-5005. The majority owner of Sotio, PPF Group, invested $6.5 million in MaveriX. Statement 

> ISA Pharmaceuticals received a €20 million loan from the European Investment Bank. The loan will fund development of a treatment for HPV16-positive cancers. Release  

> The FDA granted organ drug designation to Minoryx Therapeutics’ leriglitazone in Friedreich’s ataxia. Statement  

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.